Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation

Leuk Res. 2011 Mar;35(3):422-3. doi: 10.1016/j.leukres.2010.10.025. Epub 2010 Nov 18.

Authors

Federica Sorà¹, Patrizia Chiusolo, Elisabetta Metafuni, Silvia Bellesi, Sabrina Giammarco, Luca Laurenti, Giuseppe Ausoni, Gina Zini, Alina J Bayer, Balducci Mario, Giuseppe Leone, Simona Sica

Affiliation

¹ Institute of Haematology, Università Cattolica Sacro Cuore, Roma, Italy. [email protected]

PMID: 21093053
DOI: 10.1016/j.leukres.2010.10.025

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / therapeutic use
Benzenesulfonates / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Gastrointestinal Diseases / drug therapy*
Gastrointestinal Diseases / etiology
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Humans
Inverted Repeat Sequences / genetics
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / therapy
Male
Middle Aged
Mutation / genetics
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / therapeutic use*
Salvage Therapy
Skin Diseases / drug therapy*
Skin Diseases / etiology
Sorafenib
Stem Cell Transplantation / adverse effects*
Tandem Repeat Sequences / genetics
Transplantation, Homologous
Young Adult
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Pyridines
Niacinamide
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3